Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.83 Average PT from Analysts

Tyra Biosciences, Inc. (NASDAQ:TYRA) has received an average recommendation of “Buy” from the six analysts that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued a report on the stock in the last year is $30.83.

TYRA has been the topic of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, March 28th. Piper Sandler started coverage on Tyra Biosciences in a research note on Wednesday, May 21st. They issued an “overweight” rating and a $33.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, March 31st.

Tyra Biosciences Price Performance

NASDAQ:TYRA opened at $10.55 on Friday. The firm has a market cap of $560.10 million, a price-to-earnings ratio of -6.55 and a beta of 1.07. The firm’s fifty day moving average price is $9.31 and its 200 day moving average price is $12.12. Tyra Biosciences has a 1-year low of $6.42 and a 1-year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. As a group, analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tyra Biosciences

Several hedge funds have recently bought and sold shares of the company. Rhumbline Advisers grew its holdings in Tyra Biosciences by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock valued at $364,000 after purchasing an additional 1,027 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Tyra Biosciences in the 4th quarter worth about $60,000. RA Capital Management L.P. grew its stake in Tyra Biosciences by 2.1% in the 4th quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company’s stock valued at $147,858,000 after acquiring an additional 220,681 shares during the last quarter. Deutsche Bank AG grew its stake in Tyra Biosciences by 52.0% in the 4th quarter. Deutsche Bank AG now owns 18,909 shares of the company’s stock valued at $263,000 after acquiring an additional 6,466 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Tyra Biosciences during the 4th quarter valued at about $761,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.